1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Biosimilar Avastin Is Launched In India

Cadila Pharmaceuticals Announces Entry

 
• By Dean Rudge

Outlining plans to launch “multiple biosimilar products this year for the Indian market,” Cadila Pharmaceutical has just rolled out a biosimilar to Avastin (bevacizumab) in its domestic market.

IndianPill
Cadila says it plans to launch “multiple biosimilar products this year for the Indian market.” • Source: Shutterstock

Cadila Pharmaceuticals Ltd., the privately-owned Indian player, says it has expanded its oncology portfolio by introducing a biosimilar to Avastin (bevacizumab) in its local market.

Named Bevaro, the biosimilar will be made available in a single dose vial of two strengths, 100mg and 400mg.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

Henlius And Organon Sued In US Over Plans To Market Perjeta Biosimilar

 
• By Dean Rudge

Roche and its Genentech subsidiary have sued Shanghai Henlius Biotech and commercialization partner Organon in the US, alleging infringement of 24 patents covering Perjeta (pertuzumab). The litigation follows Roche’s recent disclosure that biosimilars to Perjeta could launch as soon as 2026.

Accord Takes On Ustekinumab Rivals In US With Steepest Discount Yet

 
• By Dave Wallace

Boasting the “lowest WAC price among branded biosimilars to Stelara”, Accord BioPharma has launched its Imuldosa version of ustekinumab in the US at a 92% discount to the blockbuster immunology brand.

Formycon’s Search For Keytruda Biosimilar Partner Is Key To Deliver FY2025 Guidance

 
• By Urtė Fultinavičiūtė

With H1 revenues not even hitting double-digits, Formycon is bidding on partnerships and royalties to generate at least €46m over the next half-year to reach its revenue goal.

Byooviz US Launch Slated For 2026 As Harrow Touts Immediate Uptake Potential

 
• By Dean Rudge

Harrow is taking aim at launching new partner Samsung Bioepis’ Byooviz biosimilar to Lucentis in 2026.

More from Products

Zydus Looks To Ride gIbrance Exclusivity Wave; GLP-1 Battle-Ready With Differentiated Pen

 
• By Vibha Ravi

Ibrance is losing share to other drugs, but Zydus looks forward to a late 2027/early 2028 launch of its generic in the US where partner Synthon might have 180-day exclusivity. In India, as Lilly launches Mounjaro KwikPen, it hopes for a GLP-1 edge with a differentiated device and formulation.

Formycon’s Search For Keytruda Biosimilar Partner Is Key To Deliver FY2025 Guidance

 
• By Urtė Fultinavičiūtė

With H1 revenues not even hitting double-digits, Formycon is bidding on partnerships and royalties to generate at least €46m over the next half-year to reach its revenue goal.

$160m War Chest Readied For Aquestive’s Oral Epinephrine Film Launch

 
• By Dean Rudge

Filed through the FDA’s 505(b)(2) hybrid new drug application pathway, Aquestive Therapeutics’ proposed Anaphylm (epinephrine) sublingual film has received major financial backing with a pair of funding deals.